

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

# **Laser-Assisted In Situ Keratomileusis (LASIK) Lasers - Patient Labeling Recommendations**

---

## **Draft Guidance for Industry and Food and Drug Administration Staff**

***DRAFT GUIDANCE***

**This draft guidance document is being distributed for comment purposes only.**

**Document issued on July 28, 2022.**

You should submit comments and suggestions regarding this draft document within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <https://www.regulations.gov>. Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Identify all comments with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions about this document, contact the OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices/DHT1A: Division of Ophthalmic Devices at (301) 796-5620.



**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Devices and Radiological Health**

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

# Preface

## Additional Copies

Additional copies are available from the Internet. You may also send an email request to [CDRH-Guidance@fda.hhs.gov](mailto:CDRH-Guidance@fda.hhs.gov) to receive a copy of the guidance. Please include the document number 16053 and complete title of the guidance in the request.

DRAFT

## **Table of Contents**

I. Introduction.....	1
II. Background.....	2
III. Scope .....	3
IV. Patient Labeling Components.....	4
A. General Considerations .....	4
B. Suggested Format and Content of Patient Labeling.....	5
(1) Description of the Eye and the Surgery.....	6
(2) Purpose of the Device (Indications for Use) .....	6
(3) What are the Benefits?.....	6
(4) What are the Alternatives? .....	6
(5) Contraindications, Warnings, and Precautions.....	6
(6) What are the Risks? .....	14
(7) What to Expect Before, During, and After Surgery .....	19
(8) Clinical Study Information .....	20
(9) Contact Information.....	20
(10) Patient Decision Considerations .....	20
Appendix A: Patient Decision Checklist Example.....	22

# Laser-Assisted In Situ Keratomileusis (LASIK) Lasers - Patient Labeling Recommendations

## Draft Guidance for Industry and Food and Drug Administration Staff

*This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or we) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page.*

### I. Introduction

This draft guidance recommends content and formatting for patient labeling information for laser-assisted in situ keratomileusis (LASIK) devices. FDA is issuing this guidance to help ensure that both physicians can share and patients can understand information on the benefits and risks of these devices. The recommendations are being made based on concerns that some patients are not receiving and/or understanding information regarding the benefits and risks of LASIK devices. These labeling recommendations are intended to enhance, but not replace, the physician-patient discussion of the benefits and risks of LASIK devices that uniquely pertain to individual patients.

For the current edition of the FDA-recognized consensus standard(s) referenced in this document, see the [FDA Recognized Consensus Standards Database](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm).<sup>1</sup> For more information regarding use of consensus standards in regulatory submissions, please refer to the FDA guidance titled “[Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appropriate-use-voluntary-consensus-standards-premarket-submissions-medical-devices).”<sup>2</sup>

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. FDA guidance documents, including this guidance, should be viewed only as recommendations, unless

<sup>1</sup> Available at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm>.

<sup>2</sup> Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/appropriate-use-voluntary-consensus-standards-premarket-submissions-medical-devices>.

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

33 specific regulatory or statutory requirements are cited. The use of the word *should* in Agency  
34 guidance means that something is suggested or recommended, but not required.  
35

## 36 **II. Background**

37 LASIK is an outpatient refractive surgery procedure used to help correct refractive errors to  
38 reduce dependency on eyeglasses. Refractive errors arise when the shape of the cornea (the clear,  
39 round dome at the front of the eye) and the eye are not perfect and the image on the retina is out-  
40 of-focus (blurred) or distorted. These imperfections in the focusing power of the eye are called  
41 refractive errors, such as myopia (nearsightedness), hyperopia (farsightedness), and  
42 astigmatism. In a LASIK procedure, a laser is used to reshape the cornea to improve the way the  
43 eye focuses light rays onto the retina at the back of the eye. LASIK is currently one of the most  
44 commonly performed elective procedures in the world, as well as the most popular form of  
45 refractive surgery that patients choose to correct common vision problems such as  
46 nearsightedness, farsightedness, and astigmatism.<sup>3</sup>  
47

48 On April 25, 2008, FDA convened its Ophthalmic Devices Panel of the Medical Devices  
49 Advisory Committee to discuss recommendations for modifications to patient labeling of  
50 excimer lasers for LASIK as well as other LASIK-related activities. During this meeting, patient  
51 advocacy groups also highlighted the importance of clearly communicating the risks of LASIK.<sup>4</sup>

52 Since the time of the LASIK Advisory Committee meeting, FDA has continued to gather new  
53 information pertaining to risks associated with LASIK, including dry eye, pain and discomfort,  
54 and visual symptoms. Clinical and scientific knowledge about these events and symptoms has  
55 increased since the time of the last advisory committee meeting. FDA has diligently collaborated  
56 with external experts on research efforts, including focus groups, to better characterize risks to  
57 ensure that the recommended labeling discussed in this guidance addresses the concerns  
58 uncovered in this collaboration and that risk information is communicated in an understandable  
59 format.

60 As one example of these efforts, in October 2009, the FDA, the National Eye Institute (NEI), and  
61 the Department of Defense (DoD) launched the LASIK Quality of Life Collaboration Project  
62 (LQOLCP) to better understand the potential risk of severe problems that can result from  
63 LASIK.<sup>5</sup> At the time the collaboration partners developed the project, there was a limited amount  
64 of valid scientific data on certain patient-reported outcomes (PROs) related to LASIK. A PRO is  
65 a report of how patients feel and function reported by the patient, not the health care provider.  
66 The Patient-Reported Outcomes with LASIK (PROWL) studies in the LQOLCP assessed visual

---

<sup>3</sup> Vitale, S., et al., Costs of refractive correction of distance vision impairment in the United States, 1999-2002. *Ophthalmology*, 2006. 113(12): p. 2163-70.

<sup>4</sup> One Hundred and Tenth Meeting of the Ophthalmic Devices Panel of the Medical Devices Advisory Committee, Laser-assisted in situ keratomileusis (LASIK) Post Market Experience, April 25, 2008, <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfAdvisory/details.cfm?mtg=695>.

<sup>5</sup> For additional information on the LASIK Quality of Life Collaboration Project, see <https://www.fda.gov/medical-devices/lasik/lasik-quality-life-collaboration-project>.

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

67 symptoms before and after LASIK surgery to identify changes over time. There were multiple  
68 phases to the PROWL studies, the final of which was completed in 2014. Although not the focus  
69 of the studies, the information gathered regarding risks and patient experiences were informative  
70 to these guidance recommendations.

71 In addition, FDA is aware that patients may not be receiving information in a format that allows  
72 them to make a well-informed decision about whether to have LASIK. The recommendations in  
73 this guidance are being made to help ensure that patients are informed of the significant risks  
74 associated with LASIK prior to choosing this type of surgery and are informed by the latest  
75 information about these devices.

76  
77 FDA is issuing this draft guidance to reflect the Agency's current thinking on labeling specific to  
78 LASIK devices, and to enable the public to comment on these recommendations, including the  
79 recommended language for inclusion in patient labeling and a patient decision checklist, as  
80 described below. FDA believes this information, in conjunction with physician-patient  
81 discussion, will help to ensure that a patient receives relevant information on and understands the  
82 benefits and risks associated with LASIK so that the patient can make an informed decision as to  
83 whether the procedure is the right choice for him/her prior to undergoing the procedure. In  
84 addition, the Agency will continue to monitor information about potential safety risks and take  
85 steps to ensure they are being adequately conveyed to and understood by physicians and patients.  
86

### **87 III. Scope**

88 This draft guidance recommends content and formatting of patient labeling information for  
89 LASIK devices, including a patient decision checklist. This draft guidance applies to all  
90 refractive lasers with LASIK indications for use (FDA product code LZS).<sup>6</sup>

91  
92 LASIK devices are prescription devices and are exempt from having adequate directions for lay  
93 use required under section 502(f)(1) of the FD&C Act (21 U.S.C. § 352(f)(1)) as long as the  
94 conditions in 21 CFR 801.109 are met. FDA believes it is important for patients considering  
95 LASIK surgery to have the information they need for a balanced discussion of benefits and risks  
96 with their physicians. It is also important for physicians to know how to educate their patients  
97 about risks that might arise as a result of LASIK surgery. As such, FDA believes it is important  
98 for manufacturers to include information for both physicians and also for patients about the risks  
99 of the device – including but not limited to information that can inform the patient of the possible  
100 risks to health associated with LASIK surgery. This information should appear in a format that a  
101 physician can easily convey directly to the patient. To help ensure that both physicians and  
102 patients receive and have this information, patient labeling, including a patient decision  
103 checklist, should be provided by manufacturers and given to physicians and patients prior to a  
104 LASIK procedure, and should include considerations related to procedural information,

---

<sup>6</sup> Other ophthalmic laser devices, such as those indicated for photorefractive keratectomy under FDA product code LZS and those covered by FDA product code OTL, are not contemplated by and therefore outside the scope of this draft guidance.

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

105 candidate considerations, benefits/alternatives, contraindications, warnings and precautions, and  
106 specific health risk information.

107  
108 Accurate product labeling and effective communication of that labeling is important to make  
109 device users and patients aware of the risks associated with LASIK devices. Moreover, a device  
110 shall be deemed misbranded if, among other things: its labeling is false or misleading; its  
111 labeling does not contain adequate warnings; or any information required to be in the labeling is  
112 not prominently placed with such conspicuousness and in such terms to render it likely to be read  
113 and understood by the ordinary individual under customary conditions of purchase and use (see  
114 sections 502(a), 201(n), 502(c), and 502(f)(2) of the Federal Food, Drug, and Cosmetic Act  
115 (FD&C Act)).<sup>7</sup> FDA intends to work with manufacturers of new LASIK devices through the  
116 premarket approval application (PMA) process, and manufacturers of currently marketed LASIK  
117 devices through the PMA supplement process, to integrate these important labeling  
118 recommendations. Since it is anticipated that such a change will enhance the safe use of the  
119 device, updated labeling may qualify for a submission as a Special PMA Supplement -- Changes  
120 Being Effected.<sup>8</sup>

121  
122 This guidance should be used as a complement to FDA’s, “[Guidance on Medical Device Patient](#)  
123 [Labeling](#)” (which describes FDA’s current thinking on making medical device patient labeling  
124 understandable to and usable by patients), existing regulations, and other relevant guidance  
125 documents containing additional labeling recommendations.<sup>9</sup>

126

## 127 **IV. Patient Labeling Components**

### 128 **A. General Considerations**

129 The patient labeling should be directed to potential candidates for LASIK and should address the  
130 following questions:

- 131
- 132 • What is LASIK surgery?
  - 133 • What is the specific LASIK device used for the patient’s procedure?
  - 134 • What are the approved indications for use specific to the LASIK device?
  - 135 • What makes someone a poor candidate for LASIK?
  - 136 • What factors should a patient consider in deciding whether LASIK is appropriate for  
137 him or her?
  - 138 • What are the benefits, risks, and alternatives to LASIK?

---

<sup>7</sup> Under section 301(a) of the FD&C Act, it is a prohibited act to introduce or deliver for introduction into interstate commerce any device that is misbranded.

<sup>8</sup> 21 CFR 814.39(d). For additional information, please also see “[Modifications to Devices Subject to Premarket Approval \(PMA\) – The PMA Supplement Decision Making Process](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/modifications-devices-subject-premarket-approval-pma-pma-supplement-decision-making-process)” (<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/modifications-devices-subject-premarket-approval-pma-pma-supplement-decision-making-process>).

<sup>9</sup> See “[Guidance on Medical Device Patient Labeling](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-medical-device-patient-labeling)” (<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-medical-device-patient-labeling>).

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

- 139           • What should a patient expect before, during, and after LASIK?  
140

141 Patient labeling should be written in simple, lay language that can be read and understood by  
142 prospective patients who may not be familiar with LASIK and its related terminology. Clearly  
143 labeled, relevant graphics may be used to improve patient understanding.  
144

145 Even with technically accurate lay language, poorly designed text can still be confusing and  
146 misleading. Before completing the patient labeling, the text should be tested with representative  
147 users in a controlled test situation to determine whether they comprehend the information  
148 sufficiently to understand the risks, make appropriate choices, and know what to expect from  
149 treatment with the device. During the development of the patient labeling, manufacturers should  
150 identify the critical information that the labeling needs to convey, and test it iteratively to  
151 determine whether the users comprehend that information correctly, e.g., by having users recite  
152 what they have learned. Manufacturers should also work to alter the method(s) of delivering this  
153 information, as appropriate, until users demonstrate adequate comprehension. Testing in these  
154 iterative phases may not necessitate large numbers of subjects.<sup>10</sup>  
155

156 When translating the health care provider labeling into lay language, manufacturers should  
157 ensure that there are no changes to the intent of the indications, contraindications, warnings and  
158 precautions, or other parts of the health care provider labeling. The lay translation should provide  
159 a balanced presentation of the benefits and risks of the device for the indications for use. It  
160 should not introduce new information or statements about product performance that are not in the  
161 health care provider labeling, but should instead be a reflection of the information provided in  
162 the health care provider labeling geared towards a lay audience.

## 163           **B. Suggested Format and Content of Patient Labeling**

164 FDA recommends that patient labeling also contains the information in the sections outlined in  
165 the FDA’s “[Guidance on Medical Device Patient Labeling](#).”<sup>11</sup> As recommended above, the  
166 content should be written in a way that informs patients of the benefits, risks, and alternatives to  
167 the specific indication for use of the device in simple, lay language they can understand. The  
168 sequence of the sections suggested in the guidance may be adapted as appropriate for a specific  
169 device and indication, but should enable the patient to easily find and understand information  
170 that answers the questions identified above. This section also includes informational content and  
171 format suggestions for inclusion in LASIK patient labeling.

---

<sup>10</sup> An iterative approach to usability testing is further described as part of the usability engineering process in the currently FDA-recognized version of IEC 62366-1: *Medical devices – Part 1: Application of usability engineering to medical devices*.

<sup>11</sup> Available at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-medical-device-patient-labeling>.

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

172 **(1) Description of the Eye and the Surgery**

173 **a. How Your Eye Works**

174 For this part of the labeling, FDA recommends including a brief description of the optics of the  
175 eye and the causes of refractive errors with an emphasis upon the refractive role of the cornea.  
176 FDA recommends that manufacturers include appropriate, clearly labeled diagrams to illustrate  
177 the described concepts.

178 **b. What Is LASIK and What Does the [XX] LASIK Laser Do?**

179 This part of the labeling should include a brief description of the steps of LASIK (with clearly  
180 labeled diagrams) and how the device is used to correct refractive errors consistent with the  
181 indications for use. If the device has special features, such as wavefront guidance, these could  
182 also be explained in this section.

183  
184 FDA also recommends explaining what the device and LASIK cannot do, to help ensure that  
185 patients have realistic expectations of LASIK.

186 **(2) Purpose of the Device (Indications for Use)**

187 For this part of the labeling, FDA recommends including a brief description of the FDA-  
188 approved Indications for Use in lay terms, including the key characteristics that define the  
189 intended patient population, such as the following:

- 190
- 191 • Range of the refractive error
  - 192 • Age range
  - 193 • Definition of pre-operative refractive stability

194 **(3) What are the Benefits?**

195 This part of the labeling should include a description of the specific benefits patients should  
196 expect from the device in a balanced, factual, and non-promotional manner. FDA also  
197 recommends that the description include discussion of the limitations of surgery to try to prevent  
198 potential unrealistic expectations about the results of surgery. FDA recommends that you not  
199 present the specific results of PMA studies in this section because the results are provided in a  
200 separate clinical study section (see section III.B.(8)).

201 **(4) What are the Alternatives?**

202 This part of the labeling should include an explanation that LASIK is an elective surgery, and  
203 discuss available alternatives for the correction of refractive error, both non-surgical and  
204 surgical, including their key risks and benefits.

205 **(5) Contraindications, Warnings, and Precautions**

206 This part of the labeling should include a description of the contraindications, warnings, and  
207 precautions in the patient labeling. These should be the same as those listed in the health care  
208 provider labeling (except for those related to the operation of the device) and should be written in  
209 lay terms.

## Contains Nonbinding Recommendations

### Draft – Not for Implementation

210  
211 FDA recognizes that proper patient selection is a key element in ensuring good outcomes from  
212 LASIK. Accordingly, FDA believes it is important that any included descriptions of  
213 contraindications, warnings, and precautions be presented in a way that enables patients  
214 considering LASIK to easily recognize, understand, and evaluate the characteristics and  
215 conditions that may affect their suitability as candidates for the surgery. For each  
216 contraindication, warning, and precaution, the patient labeling should include an explanation of  
217 why the condition may result in a particular problem. Because certain conditions appear in more  
218 than one of the subsections on contraindications, warnings, and precautions, FDA recommends  
219 that this information be summarized in table format, as shown in Table 1 below, as well as  
220 explained in the text of each subsection. Examples are provided in each of the subsections below.

221  
222 The following is an example summary table and text for introducing it:

223  
224 **Table 1** is a quick reference that you can use to start a conversation with your doctor about  
225 whether LASIK is right for you. Mark those characteristics or conditions that you know  
226 apply to you and discuss them with your doctor, if you are considering LASIK. Ask your  
227 doctor whether any of the other characteristics or conditions apply to you, and, if so, how  
228 they may affect your risk of LASIK complications. Greater detail is provided below the table  
229 about these characteristics and conditions and what complications or side effects may arise if  
230 you have one of them and choose to have LASIK.

231  
232 Table 1. Characteristics and Conditions Considered to Evaluate Suitability for LASIK (to be  
233 discussed with your doctor)

234  When you should not have LASIK (Contraindications)

235  When you should consider not having LASIK (Warnings)

236 \* Other things that may increase your risk of LASIK complications (Precautions)

237

Characteristic/Condition	Check the Box <input checked="" type="checkbox"/> if the Characteristic Applies to You
Dry eyes	<input type="checkbox"/>  If you have severe dry eyes <input type="checkbox"/>  If you have moderate or mild dry eyes
Cornea not thick enough	<input type="checkbox"/>  If the clear front part of your eye is not thick enough
Thinning of the cornea (see Image 1)	<input type="checkbox"/>  If you have any condition that causes thinning or bulging of the cornea, including: <ul style="list-style-type: none"><li>• Cone-shaped cornea (keratoconus)</li><li>• Thinning of the bottom part of the cornea (pellucid marginal degeneration)</li></ul> <input type="checkbox"/> * If you have a family history of thinning of the cornea

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

Eye infection	<input type="checkbox"/>  If you have an active eye infection
Eye inflammation	<input type="checkbox"/>  If you currently have an eye inflammation <input type="checkbox"/> * If you have a history of any eye disease (e.g., uveitis), abnormality, injury, or surgery
Herpes eye infection	<input type="checkbox"/>  If you have had a recent eye infection or problems resulting from a past infection <input type="checkbox"/>  If you have had a past eye infection
Autoimmune or connective tissue disease (rheumatoid arthritis, lupus)	<input type="checkbox"/>  If you have an active autoimmune or connective tissue disease <input type="checkbox"/>  If you have an autoimmune or connective tissue disease that is controlled
Glaucoma	<input type="checkbox"/>  If you have uncontrolled glaucoma (your eye pressure is too high even with treatment) <input type="checkbox"/>  If you have controlled glaucoma <input type="checkbox"/> * If you have elevated eye pressure (ocular hypertension) or are being followed for possible glaucoma
Diabetes	<input type="checkbox"/>  If you have uncontrolled diabetes (your blood sugar is not well controlled despite treatment) <input type="checkbox"/>  If you have controlled diabetes
Activities	<input type="checkbox"/>  If you participate in activities that could damage the LASIK flap, including contact sports (e.g., football) <input type="checkbox"/> * If you participate in activities that require good vision in poor lighting conditions to avoid a hazard (e.g., driving at night)
Medications	<input type="checkbox"/>  If you take medications that have dry eyes as a side effect, such as: <ul style="list-style-type: none"><li>• Isotretinoin</li><li>• Steroids</li><li>• Medications that weaken the immune system (immunosuppressants)</li></ul> <input type="checkbox"/> * If you take any of the following medications: <ul style="list-style-type: none"><li>• Amiodarone hydrochloride</li><li>• Sumatriptan</li></ul>

## Contains Nonbinding Recommendations

### Draft – Not for Implementation

Repeated attacks of sharp eye pain due to epithelial basement membrane dystrophy	<input type="checkbox"/> ⚠ If you have a condition in which the outer layer of corneal cells does not stick well to other layers (epithelial basement membrane dystrophy)
Weakened immune system	<input type="checkbox"/> ⚠ If you have a weakened immune system due to medications (such as steroids) or a medical condition (such as AIDS)
“Crossed eyes” (strabismus)	<input type="checkbox"/> ⚠ If you have “crossed eyes”
Decreased vision in one eye	<input type="checkbox"/> ⚠ If you have decreased vision in one eye
Large pupils or very nearsighted	<input type="checkbox"/> * If you have large pupils or are very nearsighted
Allergies or eye rubbing	<input type="checkbox"/> * If you have allergies or rub your eyes

238

239 If you are considering LASIK, make sure that you have been checked by your doctor for the  
240 characteristics and conditions above and let your doctor know if you have any of these  
241 characteristics or have ever experienced any of these conditions.

242

#### a. When You Should Not Have LASIK (Contraindications)

243 This section should discuss conditions or situations in which the device should not be used  
244 because the known or reasonably foreseeable risk of using the device outweighs any reasonably  
245 foreseeable benefit. For example:

246

247 Please inform your doctor if you have ANY of the following conditions, which greatly  
248 increase the risk of harm from LASIK, including possible permanent loss of vision. Your  
249 doctor may determine, based on this information and/or your clinical examination, that you  
250 should NOT have LASIK:

251

252  **Severe dry eye.** LASIK can worsen this problem, even if successfully treated before  
253 LASIK, and increase your risk of infection and/or scarring. Symptoms of dry eye may  
254 include a scratchy or sandy feeling in the eye, stinging, burning, episodes of excessive  
255 tearing, a stringy discharge from the eye, pain, redness, eye fatigue, light sensitivity,  
256 and blurred vision. If you are not able to tolerate wearing contact lenses, this may be a  
257 sign that you have dry eyes. Make sure your LASIK doctor checks you for dry eyes  
258 before having LASIK.

259


260  **Cornea not thick enough.** Your cornea (the clear front part of the eye) must be thick  
261 enough to undergo LASIK without increasing the risk of causing an abnormal bulging  
262 forward of the cornea (*ectasia*), which could decrease your vision. Ask your LASIK  
263 doctor whether the thickness of your cornea puts you at greater risk for this  
264 complication.

265

## Contains Nonbinding Recommendations

### Draft – Not for Implementation

266       ⊘ **Thinning of the cornea.** If you have a cone-shaped cornea (*keratoconus*; see Image  
267       1), thinning of the bottom part of the cornea along the edges (*pellucid marginal*  
268       *degeneration*), or any other condition that may cause a thinning or bulging of your  
269       cornea, LASIK can worsen these conditions and cause a permanent reduction in your  
270       vision. This may result in the need for additional surgery (such as a corneal  
271       transplant) after LASIK. Your LASIK doctor should map the shape of your cornea  
272       before LASIK to make sure you do not have any thinning.  
273  
274



275  
276  
277       **Image 1** Thinning of the cornea, or keratoconus<sup>12</sup>  
278

279       ⊘ **Active eye infection or active inflammation.** If you have an active infection or  
280       inflammation of the eye (such as keratitis, iritis, or uveitis), LASIK will likely make  
281       your condition worse, resulting in permanent eye damage. Let your LASIK doctor  
282       know if you are currently being treated, or if you have ever been treated, for such a  
283       condition.  
284  
285       ⊘ **Recent herpes eye infection or problems resulting from past infection.** If you  
286       have had a herpes (simplex or zoster) eye infection within the past year or you have  
287       had corneal damage from prior herpes infections, you are at higher risk for further  
288       corneal damage after LASIK. Let your LASIK doctor know if you have ever had a  
289       herpes eye infection.  
290  
291       ⊘ **Active autoimmune or connective tissue disease.** If you have an active connective  
292       tissue disease or autoimmune disease (such as rheumatoid arthritis and lupus) that can  
293       cause corneal melting, LASIK will increase your risk of severe damage to your  
294       cornea and vision loss. Let your LASIK doctor know about any medical conditions  
295       you have.  
296  
297       ⊘ **Uncontrolled glaucoma.** If you have uncontrolled glaucoma, the increased eye  
298       pressure associated with cutting the LASIK flap puts you at greater risk for loss of  
299       vision. Let your LASIK doctor know if you have been diagnosed with glaucoma.  
300

<sup>12</sup> Image from <http://www.cornea.org/Learning-Center/Conditions-Research-Areas/Keratoconus.aspx>.

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

301       ⊘ **Uncontrolled diabetes.** If your blood sugar is uncontrolled, your eyeglass  
302       prescription can fluctuate and your doctor will not be able to accurately determine  
303       what degree of LASIK treatment is appropriate. Uncontrolled diabetes can also  
304       negatively affect wound healing after LASIK. Let your LASIK doctor know if you  
305       have diabetes.

#### 306       **b. When You Should Consider Not Having LASIK (Warnings)**

307       This part of the labeling should discuss conditions under which there is reasonable evidence of  
308       an association of a serious harm with the use of the device and a person's suitability for the  
309       surgery should be carefully evaluated. This section should also provide information about the  
310       patient groups or conditions for which device safety and effectiveness has not been adequately  
311       studied, and for which use of the device would be expected to lead to adverse health outcomes or  
312       limited effectiveness, e.g., outside the approved refractive range. The following is one example  
313       of a set of warnings that follow the above recommendations:

314  
315       Please inform your doctor if you have ANY of the following conditions that may result in a  
316       greater risk for poor outcomes or injury related to LASIK. You should discuss your level of  
317       risk with your doctor. You and your doctor should determine whether the benefits to you  
318       outweigh the risks based on the nature and severity of your condition.

319  
320       ⚠ **Moderate or mild dry eyes.** If you have dry eyes, LASIK can worsen dryness,  
321       discomfort and blurred vision. This may or may not get better. If you take certain  
322       medications, such as nasal decongestants, you are at greater risk of having dry eyes. If  
323       you have a condition that can cause dry eye, such as thyroid disease, Sjögren's syndrome,  
324       lupus, or rheumatoid arthritis, you are also at greater risk. Make sure your LASIK doctor  
325       checks you for dry eyes before having LASIK.

326  
327       ⚠ **Past herpes eye infection.** If you have any history of herpes (simplex or zoster) infection  
328       in your eyes, LASIK might reactivate the infection. Let your LASIK doctor know if you  
329       have ever had an eye infection or eye inflammation.

330  
331       ⚠ **Controlled glaucoma.** If you have glaucoma, LASIK may make monitoring your eye  
332       pressure more difficult. You may also be at greater risk for damage to your vision  
333       associated with cutting the LASIK flap. The steroid drops used after the surgery may  
334       raise your eye pressure and cause glaucoma to worsen. Let your LASIK doctor know if  
335       you have been diagnosed with glaucoma.

336  
337       ⚠ **Activities that could damage the LASIK flap.** The flap is a tongue-shaped section of  
338       corneal tissue that is cut and lifted up during LASIK and which can wrinkle, move out of  
339       place, or break off even years after surgery. Participation in contact sports, like football  
340       or martial arts, increases your risk for dislocation, or even, loss of the flap. You should  
341       discuss your work activities and hobbies with your LASIK doctor prior to surgery to help  
342       determine whether LASIK is right for you. You should ask your LASIK doctor how long  
343       you should refrain from participating in certain activities following surgery. You should

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

344 also discuss with your doctor steps you can take to decrease the risk of flap dislocation or  
345 loss.

346  
347 **⚠ Controlled autoimmune or connective tissue disease.** Connective tissue diseases or  
348 autoimmune diseases (such as rheumatoid arthritis and lupus), even if well controlled and  
349 stable, may result in delayed healing and less predictable outcomes after LASIK.  
350 Depending upon your disease, its severity, and the medication(s) you are taking, there  
351 may be additional risks. These may include severe dry eye, infection, inflammation, poor  
352 healing, and corneal melting. You should discuss these additional risks with your LASIK  
353 doctor, after he or she has consulted with the other doctors who are treating you.

354  
355 **⚠ Taking isotretinoin.** This medication, usually used for acne treatment, increases your  
356 risk for dry eye and abnormal wound healing after LASIK. If you have taken or plan to  
357 take this medication, talk to your LASIK doctor and the doctor prescribing this  
358 medication about your risk.

359  
360 **⚠ Controlled diabetes.** Even if your diabetes is well controlled, you may have poor healing  
361 of your eye following LASIK.

362  
363 **⚠ Repeated attacks of sharp eye pain due to epithelial basement membrane dystrophy**  
364 **(EBMD).** In this condition, the outer layer of corneal cells does not stick well to the other  
365 corneal layers causing the outer cells to rub off easily. These recurring “scratches”  
366 (recurrent erosions) on the eye surface often cause blurred vision, pain, light sensitivity,  
367 and tearing. LASIK is likely to worsen EBMD. Let your LASIK doctor know if you have  
368 had these symptoms in the past, and ask if any signs of this condition have been noted on  
369 your eye exam.

370  
371 **⚠ Weakened immune system.** If you have a weakened immune system due to medications  
372 (such as steroids) or a medical condition (such as AIDS), you may be more prone to  
373 infection after surgery. Such conditions and medications may put you at greater risk for  
374 other complications as well, such as dry eye or abnormal wound healing. Let your LASIK  
375 doctor know about any medical conditions you have and all medications you are taking.

376  
377 **⚠ History of “crossed eyes” (strabismus).** If you are having LASIK for farsightedness and  
378 have a history of “crossed eyes” (strabismus), you may be at an increased risk of having  
379 double vision after surgery. Tell your LASIK doctor if you have ever had “crossed eyes”  
380 or double vision.

381  
382 **⚠ Decreased vision in one eye.** If you have one eye that does not see clearly, even with  
383 glasses, you should discuss this with your LASIK doctor. This condition can be due to  
384 amblyopia, a “lazy eye,” or damage from an injury or disease. With this type of  
385 decreased vision in one eye, complications that might result from LASIK in your better  
386 seeing eye could more severely impact your functioning.

387  
388

## Contains Nonbinding Recommendations

### Draft – Not for Implementation

#### 389 c. Other Things That May Increase Your Risk of LASIK Complications 390 (Precautions)

391 This part of the labeling should include precautionary statements, which can provide information  
392 regarding any special care to be taken by the doctor and/or patient to avoid mild or moderate  
393 harms. This section should include precautionary statements concerning conditions that could  
394 affect the outcomes of LASIK and are less likely to occur or are less serious than those discussed  
395 under **Warnings**. The precautions should include information about other considerations that  
396 could affect eye health, as well as patient characteristics not studied in the pivotal study, but for  
397 which adverse outcomes would not be expected with use (e.g., based on the inclusion and  
398 exclusion criteria and not already reflected in the Contraindications and Warnings). The  
399 following is one example of a set of precautions that follow the above recommendations:

400  
401 The list below provides information regarding conditions for which consideration should be  
402 given when deciding whether the benefits of LASIK with this device outweigh the risks to  
403 you. You should discuss with your LASIK doctor whether the following conditions apply to  
404 you and how they may affect your risk of having complications from LASIK:

- 405
- 406 \* **Family history of thinning of the cornea.** Eye diseases like a cone-shaped cornea  
407 (*keratoconus*), thinning of the inferior part of the cornea (*pellucid marginal*  
408 *degeneration*), and other conditions that may cause a thinning or bulging of the cornea  
409 can run in families. You may not be aware that you have such a condition if it is in the  
410 early stage. If you have one of these conditions and it has not been diagnosed, LASIK  
411 may cause more rapid progression of the disease. You should tell your LASIK doctor  
412 about any family history of these or any other eye problems.
  - 413
  - 414 \* **History of any eye disease (e.g., uveitis), abnormality, injury, or surgery.** If you have  
415 a history of any of these conditions, you should discuss them with your LASIK doctor, as  
416 they might increase the risks of LASIK. For example, corneal scars may affect LASIK  
417 accuracy and vision following the surgery.
  - 418
  - 419 \* **Taking amiodarone hydrochloride.** This medication, usually used to treat irregular  
420 heartbeats (ventricular arrhythmias), can cause cloudy areas in the cornea and may cause  
421 problems with healing after LASIK. Tell your LASIK doctor about all the medications  
422 that you are taking.
  - 423
  - 424 \* **Taking sumatriptan.** This medication, usually used to treat migraine headaches, may  
425 cause problems with healing after LASIK. Tell your LASIK doctor about all medications  
426 you are taking.
  - 427
  - 428 \* **Large pupils or very nearsighted.** Many factors affect whether someone might  
429 experience visual symptoms, making it difficult to predict who will experience them after  
430 surgery. However, very nearsighted patients and patients with large pupils may be at  
431 greater risk of experiencing visual symptoms, such as halos and glare. In addition,  
432 patients who are very nearsighted generally may have less accurate correction than those

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

433 requiring less treatment. Ask your doctor whether you have large pupils or are very  
434 nearsighted.

435  
436 \* **Activities under poor lighting conditions.** LASIK may decrease your ability to see well  
437 in poor lighting conditions, such as in dim lighting, rain, snow, and fog, when contrast  
438 (difference in how bright an object is compared to its background) is low, or when there  
439 is glare from bright lights, especially at night. You should discuss these potential  
440 problems with your LASIK doctor. After LASIK, you should be careful while driving  
441 when you are in poor lighting conditions until you can determine whether you have any  
442 difficulties.

443  
444 \* **Allergies or eye rubbing.** If you rub your eyes after you have had LASIK, you are at a  
445 greater risk for dislodging the LASIK flap. This is because the strength of the attachment  
446 of the flap to the underlying corneal layers is permanently reduced after surgery.  
447 Additionally, some allergy medications cause dry eye symptoms. If you take these  
448 medicines, you are at greater risk for severe dry eye after LASIK. Let your LASIK doctor  
449 know about all your allergies and medications (even over-the-counter medications) and if  
450 you tend to rub your eyes frequently.

451  
452 \* **Elevated eye pressure (ocular hypertension) or being followed for possible**  
453 **glaucoma.** If you have either of these conditions related to eye pressure, there are several  
454 ways LASIK can cause problems for you. It is more difficult to accurately monitor your  
455 eye pressure after LASIK, which may delay the detection of glaucoma. You may be at  
456 greater risk for damage to your vision associated with cutting the LASIK flap.  
457 Additionally, steroid drops used after surgery may raise the eye pressure and cause  
458 glaucoma to worsen. Let your LASIK doctor know if you have any of these conditions.

### 459 **(6) What are the Risks?**

460 This part of the labeling should include a description of patient risks. FDA recommends that the  
461 most severe and most frequent potential risks and complications, both associated with LASIK in  
462 general and with the device to be used, are discussed first, followed by all others (e.g.,  
463 headaches, reading difficulty). Manufacturers should define all medical terms used in this section  
464 in a glossary and include every medical term in parentheses in the text following a plain  
465 language description of the term. FDA recommends including clearly labeled images to help  
466 explain visual symptoms when possible. The following is one example of a set of risk  
467 descriptions that follow the above recommendations:

468  
469 Some problems that patients experience after LASIK commonly occur right after surgery and  
470 are usually greatly reduced within 3 to 6 months. However, in some patients these problems  
471 can be permanent and, in rare cases, may impact their ability to perform daily tasks.

472  
473 The risks of LASIK include, but are not limited to, the following:

474  
475 • **Loss of vision.** This means that vision becomes unclear (blurry or hazy vision) even with  
476 glasses or contact lenses. Your doctor may be able to measure this loss using a vision

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

477 chart. The loss may be mild or, in rare cases, severe. In extremely rare cases, people can  
478 experience a total loss of vision. Vision loss is usually temporary, but there are  
479 complications of LASIK that can cause permanent loss of vision. How clearly you can  
480 see may change from day-to-day or even from minute-to-minute (fluctuating vision).  
481 Some of the potential causes of vision loss following LASIK are discussed below.

482  
483 ○ **Corneal complications.** The following corneal complications may lead to permanent  
484 vision loss, for example, due to loss of corneal clarity from scarring or swelling, and  
485 may require corneal transplant surgery for treatment:

486  
487     ▪ **Corneal flap complications.** LASIK requires the cutting of a flap of the front-  
488 most part of the cornea. The flap is swung out of the way so the laser can treat  
489 underlying tissue, and is returned to its original position after the treatment. Flap  
490 complications include irregular cutting of the flap, the flap not properly returning  
491 to its original position, the flap coming off and even getting lost, and irregular  
492 healing. If a flap complication occurs during surgery, the surgery may need to be  
493 interrupted and rescheduled. A flap complication can result in the need for  
494 additional surgery or, rarely, permanent loss of vision. In almost all LASIK cases,  
495 the strength of the flap's re-attachment to the underlying tissue is significantly and  
496 permanently weaker than before LASIK. There are reports of the flap being torn  
497 off, even many months after surgery. It may be necessary to wear protective  
498 eyewear during certain physical activities like contact sports.

499  
500     ▪ **Infection.** The cornea may get infected right after surgery. This can be treated  
501 with topical medication, which may or may not successfully control the infection.  
502 On rare occasions, an infection may cause a hole in the clear covering of the eye  
503 (perforation of the cornea).

504  
505     ▪ **Inflammation.** Inflammation after LASIK is the body's reaction to such things as  
506 tissue disruption from surgery or infection. Excessive inflammation of the cornea  
507 can cause scarring or swelling resulting in cloudiness or haziness (loss of corneal  
508 clarity).

509  
510     ▪ **Irregular corneal shape.** LASIK or the healing process after surgery may result  
511 in an irregular shape to the cornea. This can cause blurry vision or other visual  
512 symptoms. Such irregularities in shape can be measured by your doctor using  
513 special instruments.

514  
515         • **Bulging of the cornea (corneal ectasia)** is the most extreme irregularity. This  
516 complication is uncommon, but can cause permanent and significantly blurry  
517 vision, sometimes requiring a corneal transplant.

518  
519 ○ **Retinal detachment.** The retina is the light-sensitive tissue that lines the inside back  
520 of the eye and captures images that are transmitted to the brain, much like the film of  
521 a camera. If the retina detaches, or comes unglued from its attachments within the

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

522 eyeball, it will lose its function and need to be reattached through surgery. This may  
523 result in permanent loss of vision, even if the retina is successfully reattached. Retinal  
524 detachment after LASIK is rare, and usually only occurs in people who are very  
525 nearsighted and are prone to this type of retinal problem.  
526

- 527 • **Dry eyes.** LASIK may cause or increase eye dryness, which may also cause discomfort  
528 and visual problems. The doctor may see dry spots on the normally-moist portions of the  
529 cornea, or surface damage caused by dryness. These problems usually improve within 3  
530 to 6 months, but in rare cases never go away.  
531

532 If you have dry eye before surgery, LASIK may increase dry eye symptoms and related  
533 problems after surgery. Your doctor should test you for pre-existing dry eye. However,  
534 there is no test that can guarantee whether you will, or will not, have dry eye after  
535 LASIK. Lubricating drops are usually necessary immediately after surgery to help with  
536 dryness. Symptoms of dry eye may include a scratchy or sandy feeling as if something is  
537 in your eye, stinging, burning, episodes of excessive tearing, a stringy discharge from the  
538 eye, pain, redness, light sensitivity, and blurred vision. The sensation of dryness can vary  
539 from mild to severe, but in most cases the feelings are a minor annoyance. Eye drops  
540 such as artificial tears, or other treatments, such as plugs in the tear drainage system of  
541 the eye, may reduce these symptoms, but may not completely resolve them. A small  
542 number of patients experience extreme discomfort that interferes with their ability to do  
543 daily tasks.  
544

- 545 • **Discomfort or pain.** It is not unusual for patients to have some mild discomfort right  
546 after LASIK, but it usually goes away within a few weeks or months. Complications like  
547 dry eye, inflammation, or infection may cause severe, constant pain in some patients,  
548 preventing them from doing their normal activities. **In some patients, the pain may  
549 never go away (i.e., chronic pain) and may be resistant to therapy.**  
550

- 551 • **Visual Symptoms.** LASIK may cause or worsen visual symptoms, such as glare, halos,  
552 starbursts, and ghost images/double images, most commonly experienced in dim lighting  
553 conditions as well as blurred and fluctuating vision. These problems usually improve  
554 within 3 to 6 months after surgery, but in some cases never go away, even when glasses  
555 are worn. Visual symptoms can be mild, but can also be severe enough to cause  
556 difficulties in performing daily tasks. **A common complaint is difficulty with driving at  
557 night.** Specific visual symptoms are described below with images to help explain the  
558 visual symptoms. The images shown may not represent exactly what you might see, and  
559 your symptoms may be more or less severe than what is shown:  
560

- 561 ○ **Glare.** Glare is *difficulty seeing well when there are bright lights* like headlights or  
562 sunlight, as shown in the images below.  
563

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

No Glare ←————→ Severe Glare



564  
565  
566  
567  
568

- **Halos.** You may see halos. By halos, we mean *seeing a fuzzy cloud of light around lighted objects*, such as the ones shown in the images below.

No Halo ←————→ Severe Halo



569  
570  
571  
572  
573

- **Starbursts.** You may see *rays of light coming from lighted objects*, such as in the car headlights in the images below.

No Starburst ←————→ Severe Starburst




574

## Contains Nonbinding Recommendations

### Draft – Not for Implementation

- 575  
576  
577  
578  
579  
580  
581  
582  
583
- **Double vision.** *Double vision*, which some people call “ghost” or “shadow” images, are *distorted or blurry visual images*, such as the ones shown below. If you experience such images, close one eye and then the other to determine if you only see the double images with both eyes open. If you still have double vision with one eye closed, note in which eye you are experiencing the double images. This information is important to report back to your doctor to help him or her determine the cause of the problem.



- 584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607
- **Decreased ability to see under low lighting conditions.** You may have more difficulty seeing in low lighting conditions after surgery than before surgery. For example, some patients describe having more trouble reading the menu in a dimly lit restaurant or climbing down stairs in a theater. Driving during certain periods of the day, such as dusk and dawn, may become difficult, because of trouble reading signs, distinguishing the curb from the road, and being able to see people crossing the street. Some people have reported having so much difficulty seeing under these types of conditions that they avoid doing certain activities.
  - **Potential risk of psychological harm.** There have been reports that some patients who have had LASIK have experienced severe depression or suicidality that they believe to be a result of complications following the procedure. A definitive causal link between LASIK and these reported psychological harms has not been established.
  - **Desired correction not achieved or does not last.** LASIK may not result in the desired amount of vision correction, or the level of vision correction may decrease over time. Additional corrective surgery may not always be possible, and when it is possible may not result in the desired correction. Even if your vision results are generally good, you may still need glasses or contact lenses to perform certain tasks.
  - **Unintentional imbalance between two eyes.** LASIK may cause an imbalance between the two eyes if the desired correction is not achieved, or one eye is treated with LASIK

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

608 but the other eye cannot undergo LASIK. Imbalances between the two eyes may cause  
609 headaches, eyestrain, double vision, and reduced depth perception, if both eyes are not  
610 able to focus at the same time at the same distance (anisometropia).  
611

- 612 • **Need for glasses for close work.** Almost all people in their 40s or older lose their ability  
613 to focus from far to near. LASIK does not treat this condition (called “presbyopia”). After  
614 surgery, patients who are already over 40 years old (or once they reach their 40’s) usually  
615 need to wear glasses for close work, such as reading, even if they did not need to wear  
616 them before surgery.  
617
- 618 • **Drooping eyelid.** The lid of the eye(s) that had surgery may droop. This can be a  
619 complication from an instrument used to hold the lid during surgery. Besides the  
620 appearance of unevenness in the height of the eyelids, this may result in a feeling of the  
621 eyes getting tired during the course of the day or difficulty seeing, and may require eyelid  
622 surgery.  
623
- 624 • **Future eye health.** LASIK will likely cause difficulties with:
  - 625 ○ **Future assessment of eye pressure.** Thinning of the cornea due to LASIK will affect  
626 your eye pressure measurements (used as part of the exam for glaucoma), making  
627 them more difficult to interpret. You should inform all eye care providers that you  
628 have had LASIK.  
629
  - 630 ○ **Future cataract surgery.** Almost everyone needs cataract surgery (removal of your  
631 natural lens) later in life. LASIK may make it more difficult for the surgeon to  
632 implant the correct artificial lens. You should ask your LASIK doctor for a patient  
633 information card (e.g., the “K-Card” found at  
634 <http://www.geteyesmart.org/eyesmart/upload/kcard.pdf>) that lists your eye  
635 measurements before you have LASIK. You should keep this card to help the cataract  
636 surgeon accurately calculate the artificial lens power you will need when you have  
637 cataract surgery in the future.  
638

639  
640 See the **Clinical Study Section** to find out how often specific problems occurred in those  
641 treated with the [XX] laser in clinical studies of the device.

### 642 **(7) What to Expect Before, During, and After Surgery**

643 This part of the labeling should include a description of what a patient should expect before (e.g.,  
644 informing the LASIK doctor about all medications and all eye and medical conditions,  
645 discontinuation of contact lens wear, typical preoperative instructions), during, and after a  
646 surgical procedure, including typical postoperative care instructions (e.g., medications,  
647 limitations on activities). It is also recommended that approximate postoperative times that  
648 various symptoms may be experienced are included in this part of the labeling, along with  
649 explanations of what symptoms may be indicative of adverse events and under what  
650 circumstances patients should contact their doctors.

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

#### 651 **(8) Clinical Study Information**

652 This part of the labeling should include descriptions of clinical study information relevant and  
653 specific to the LASIK device to be used in the procedure. The clinical study information  
654 provides specific context about the LASIK device to be used in the procedure, such as rates and  
655 types of adverse events and visual symptoms, and patient reported outcomes. Given the  
656 complexities of clinical studies, this information should be described in a way that is meaningful  
657 to patients and easy to understand. Tables, graphs, and other technical information should be  
658 made as “readable” and “understandable at a glance” to the patient as possible, and should  
659 complement any textual descriptions. FDA recommends using lay terms rather than technical  
660 words and acronyms, that all symbols and abbreviations included in the tables and graphs be  
661 clearly defined, and that any tables or graphs contain brief explanations of what information is  
662 shown.

663  
664 FDA recommends including the purpose and main objectives of the study in this part of the  
665 labeling, which should contain a very brief description of the general study design, including the  
666 number of months that patients were followed, the number of patients studied, the key evaluation  
667 time points, and the primary and secondary safety and effectiveness endpoints.

668  
669 Further, the key safety and effectiveness outcomes of the study should be summarized in lay  
670 terms, including tabulation and accompanying explanation of the adverse events and  
671 complications that occurred during the course of the trial, symptoms, and any patient-reported  
672 outcomes. FDA recommends that you do not use percentages to summarize the outcome  
673 information, but rather the actual number of subjects in the numerator and denominator to  
674 represent rates (e.g., “45 of the 302 patients seen at the 12-month visit”), when applicable.  
675 Results of contrast sensitivity testing should be briefly summarized in lay terms with the number  
676 of subjects that underwent testing and the outcomes from the perspective of whether losses were  
677 experienced under each of the various testing conditions.

#### 678 **(9) Contact Information**

679 This part of the labeling should contain the manufacturer’s contact information, including the  
680 address and phone number, as well as blank lines that can contain the provider’s and surgical  
681 center’s names, addresses, and phone numbers.

#### 682 **(10) Patient Decision Considerations**

683 FDA believes that a patient decision checklist highlighting key risk information should be  
684 included at the end of the patient labeling. To help ensure the material is reviewed, FDA  
685 recommends the checklist allow for patients and physicians to affirmatively acknowledge (e.g.,  
686 via initials and/or signatures) that specific information was read and discussed. Additionally,  
687 FDA recommends that it should be printed in a fashion where it can be easily separated and  
688 marked.

689 To help ensure the checklist is read and understood by patients, FDA is providing  
690 recommendations regarding content and organization below. First, in the introduction for the  
691 checklist, FDA recommends including a description of the purpose and importance of the

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

692 checklist, as well as instructions to the patient on how to review and complete the document  
693 prior to deciding whether to undergo the procedure. Next, to achieve the goals described above,  
694 FDA recommends that each topic grouping in the body of the checklist be accompanied by a line  
695 for the patient to initial indicating acknowledgment and understanding of that information. At the  
696 end, FDA recommends including a section that confirms that the patient has read the patient  
697 labeling material and has had the opportunity to satisfactorily discuss the patient's risks with his  
698 or her eye surgeon. This should be followed by a signature line for the patient. At the end of the  
699 checklist, FDA recommends having a section that confirms that the physician discussed the  
700 benefits, risks, and alternatives of the device, as set forth in the patient labeling, including the  
701 patient decision checklist, with the patient. FDA recommends that this be followed by a signature  
702 line for the physician.

703  
704 The FDA recommends that a copy of the patient decision checklist be provided to the patient so  
705 that the patient can refer back to this important information. The FDA also encourages device  
706 manufacturers to develop a plan to ensure that patients are adequately informed of the risks of  
707 LASIK.

708  
709 Appendix A provides an example of a patient decision checklist. FDA believes that the form and  
710 content of the patient decision checklist will help to ensure that patients have adequate and  
711 salient information about the risks and warnings of LASIK surgery, with appropriate prominence  
712 and conspicuousness such that it is easily read and understood. The rates of certain adverse  
713 events identified in the patient decision checklist were based on information from clinical trials,  
714 scientific literature, and reports from patients who have undergone LASIK. FDA recommends  
715 using these rates unless compelling data regarding the rates of certain events have been collected  
716 with post-market experience on a specific device, particularly for the more rare adverse events.  
717

718 **Appendix A: Patient Decision Checklist Example**

719

720 To the patient considering LASIK surgery:

721

722 The review and understanding of this document is a critical step in making the decision whether  
723 you should choose LASIK surgery. You should carefully consider the benefits and risks  
724 associated with the surgery before you make that decision. This form lists important risks,  
725 including those known or reported to be associated with the use of the LASIK laser devices  
726 based on information from clinical trials, scientific literature, and reports from patients who have  
727 undergone LASIK. After reviewing the information in the patient labeling for the specific  
728 LASIK laser that will be used, please read and discuss the items in this checklist with your  
729 doctor. You should place your initials in the location provided next to each item to indicate that  
730 you have read and understood the item. Your full signature at the end of this document means  
731 that you have read and understood the materials and that your physician has answered all  
732 questions to your satisfaction.

733

734 **Vision Correction Options**

735 I understand that eyeglasses or contact lenses are proven methods for vision correction, and that  
736 photorefractive keratectomy (PRK) is an alternative surgical method for vision correction. I also  
737 understand that small incision lenticule extraction (SMILE) may be another surgical alternative  
738 for me if I am nearsighted, and conductive keratoplasty may be an alternative procedure for me if  
739 I am farsighted. I was also informed of the associated benefits and risks of other alternatives.  
740 I understand that LASIK may not result in the desired amount of vision correction. Even if my  
741 vision results are generally good, I may still need glasses or contact lenses to perform certain  
742 tasks, and the results achieved may decline over time.

743

744 I understand that during LASIK surgery, a flap is cut in the cornea and corneal tissue is  
745 vaporized.

- 746
- 747 • Corneal tissues and nerves cut during this process must heal following surgery. Corneal  
748 nerves may not fully recover resulting in dry eyes and/or chronic pain.
  - 749 • Even after the corneal flap has fully healed, the cornea will not be as strong as it was  
750 before surgery.

750

751 Patient Initials: \_\_\_\_\_

752

753 **Considerations for a good candidate for LASIK surgery**

754 I understand that I should not have LASIK surgery while I have an active eye inflammation or  
755 infection.

756

757 I understand that I am not a good candidate for LASIK if:

758

- 759 • I have severe dry eyes.
- My cornea(s) is not thick enough.

## Contains Nonbinding Recommendations

### Draft – Not for Implementation

- 760
- 761
- 762
- 763
- 764
- My doctor has told me that I have a condition that causes thinning or bulging of the cornea, such as keratoconus or pellucid marginal degeneration.
  - I have problems resulting from a past herpes eye infection.
  - I have an autoimmune disease or connective tissue disease (like lupus or rheumatoid arthritis), glaucoma, or diabetes.

765

766 Patient Initials: \_\_\_\_\_

767

#### What to Expect in the First Six Months.

768

769 I understand that dry eye following surgery is common, and the symptoms of dry eye, including

770 blurred vision, can vary from mild to severe. Based on the estimates below, I am prepared to

771 regularly use lubricating eyedrops to manage dry eye symptoms.

772

773 I understand that, following LASIK surgery, estimates of certain common risks are as follows:

- 774
- 775
- 776
- 777
- 778
- 779
- 780
- 781
- 782
- 783
- 784
- One (1) week following surgery, up to 85% of patients experience dry eye symptoms.
  - At six (6) months following surgery:
    - Up to 27% of patients experience dry eye symptoms.
    - About 41% of patients may experience visual symptoms such as glare, halos, starbursts, and double images, as illustrated in Figure 1 (with or without glasses or contact lenses).
    - Around 4% of patients may have “very” or “extremely” bothersome symptoms.
    - Around 2% may have “a lot of difficulty” or “so much difficulty that I can no longer do some of my usual activities” when not wearing glasses or contact lenses.



785 Figure 1a: Glare



786 Figure 1b: Halo



787 Figure 1c: Starburst



788 Figure 1d: Double Vision

789 Patient Initials: \_\_\_\_\_

790

#### Long-term Risks

- 791
- 792
- 793
- 794
- 795
- 796
- I understand that, although rare, there have been reports that some patients who have had LASIK have experienced severe depression or suicidality that they believe to be a result of complications following the procedure. A definitive causal link between LASIK and these reported psychological harms has not been established.
  - I understand that dry eye may persist beyond six (6) months.
  - I acknowledge the following estimates of the percentage of patients experiencing the persistence of certain symptoms five (5) years after surgery:

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807

- Around 17% of patients may still need to use eye drops daily for dry eye.
- Less than 2% of patients notice some visual disturbance, such as glare, halos, starbursts, and double vision.
- A decreased ability to see under low light conditions; around 8% of patients may have moderate difficulty or a lot of difficulty driving at night.
- Very rare reports (estimated rate of less than 0.8%) of severe, constant pain that may prevent normal activities.

Patient Initials: \_\_\_\_\_

DRAFT

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830

**CONFIRMATION OF DISCUSSION OF RISKS**

**Patient:** I acknowledge that I have received and read the patient labeling for the specific LASIK laser that will be used during my LASIK surgery and that I have had time to discuss the items in it and on this document with my doctor. I have had the opportunity to ask questions and understand the benefits and risks of LASIK surgery for me, given my specific health conditions. I have considered alternatives to LASIK, such as contact lenses, eyeglasses, and PRK, and their risks and benefits.

---

Patient Signature and Date

**Physician:** I acknowledge that I have discussed the benefits and risks of LASIK as described in the patient labeling, including this patient decision checklist. I have also explained the benefits and risks of the alternatives. I have encouraged the patient to ask questions, and I have addressed all questions.

---

Physician Signature and Date